Penny Stocks 2.0
7 minutes ago
$OTLC .026 Huge Phase 3 Trials are Successful, CEO Buying Shares »»
The presentation highlights OT-101, an antisense therapy targeting TGFB2, which is currently in phase 3 clinical trials for pancreatic cancer and glioblastoma. Initial reports have indicated significant clinical activity of O